Blau Farmacêutica S.A
Blau Farmacêutica S.A., a pharmaceutical company provides drug products in Brazil, Argentina, Chile, Colombia, Uruguay, Ecuador, Peru, and the United States. Its products cover various areas, such as immunology, hematology, oncology, nephrology, infectology, and anesthesiology. The company offers uterine stimulator, antirheumatic, anaesthetics, antibiotics, feminine health care, biopharmaceutical… Read more
Blau Farmacêutica S.A (BLAU3) - Total Assets
Latest total assets as of September 2025: R$3.62 Billion BRL
Based on the latest financial reports, Blau Farmacêutica S.A (BLAU3) holds total assets worth R$3.62 Billion BRL as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Blau Farmacêutica S.A - Total Assets Trend (2013–2024)
This chart illustrates how Blau Farmacêutica S.A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Blau Farmacêutica S.A - Asset Composition Analysis
Current Asset Composition (December 2024)
Blau Farmacêutica S.A's total assets of R$3.62 Billion consist of 49.1% current assets and 50.9% non-current assets.
| Asset Category | Amount (BRL) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | R$0.00 | 1.0% |
| Accounts Receivable | R$476.75 Million | 14.0% |
| Inventory | R$606.19 Million | 17.8% |
| Property, Plant & Equipment | R$0.00 | 0.0% |
| Intangible Assets | R$336.09 Million | 9.9% |
| Goodwill | R$151.66 Million | 4.5% |
Asset Composition Trend (2013–2024)
This chart illustrates how Blau Farmacêutica S.A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Blau Farmacêutica S.A's current assets represent 49.1% of total assets in 2024, a decrease from 69.6% in 2013.
- Cash Position: Cash and equivalents constituted 1.0% of total assets in 2024, down from 6.0% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 13.0% of total assets, an increase from 4.0% in 2013.
- Asset Diversification: The largest asset category is inventory at 17.8% of total assets.
Blau Farmacêutica S.A Competitors by Total Assets
Key competitors of Blau Farmacêutica S.A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Blau Farmacêutica S.A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Blau Farmacêutica S.A generates 0.51x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Blau Farmacêutica S.A generates $6.37 in net profit.
Blau Farmacêutica S.A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.90 | 3.48 | 2.20 |
| Quick Ratio | 1.85 | 2.27 | 1.30 |
| Cash Ratio | 0.00 | 0.05 | 0.00 |
| Working Capital | R$1.29 Billion | R$ 1.13 Billion | R$ 436.67 Million |
Blau Farmacêutica S.A - Advanced Valuation Insights
This section examines the relationship between Blau Farmacêutica S.A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.93 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 11.7% |
| Total Assets | R$3.41 Billion |
| Market Capitalization | $48.45 Million USD |
Valuation Analysis
Below Book Valuation: The market values Blau Farmacêutica S.A's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Blau Farmacêutica S.A's assets grew by 11.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Blau Farmacêutica S.A (2013–2024)
The table below shows the annual total assets of Blau Farmacêutica S.A from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | R$3.41 Billion | +11.73% |
| 2023-12-31 | R$3.05 Billion | +22.19% |
| 2022-12-31 | R$2.50 Billion | +7.35% |
| 2021-12-31 | R$2.33 Billion | +82.93% |
| 2020-12-31 | R$1.27 Billion | +72.34% |
| 2019-12-31 | R$738.44 Million | +24.28% |
| 2018-12-31 | R$594.15 Million | +62.35% |
| 2017-12-31 | R$365.97 Million | +15.91% |
| 2016-12-31 | R$315.72 Million | +4.12% |
| 2015-12-31 | R$303.25 Million | +15.69% |
| 2014-12-31 | R$262.11 Million | +11.33% |
| 2013-12-31 | R$235.43 Million | -- |